Katherine D. Cummins

3.0k total citations · 1 hit paper
18 papers, 595 citations indexed

About

Katherine D. Cummins is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Katherine D. Cummins has authored 18 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in Katherine D. Cummins's work include CAR-T cell therapy research (10 papers), CRISPR and Genetic Engineering (4 papers) and Virus-based gene therapy research (3 papers). Katherine D. Cummins is often cited by papers focused on CAR-T cell therapy research (10 papers), CRISPR and Genetic Engineering (4 papers) and Virus-based gene therapy research (3 papers). Katherine D. Cummins collaborates with scholars based in United States, Australia and Israel. Katherine D. Cummins's co-authors include Saar Gill, Selene Nuñez-Cruz, Adrian Cantu, John Leferovich, Saba Ghassemi, Marilia Rita Pinzone, Michael C. Milone, Joseph S. Durgin, Jai Patel and Frederic D. Bushman and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Cancer Research.

In The Last Decade

Katherine D. Cummins

16 papers receiving 589 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rapid manufacturing of non-activated potent CAR T cells

2022 184 citations Saba Ghassemi, Joseph S. Durgin et al. Nature Biomedical Engineering profile →

Peers

Countries citing papers authored by Katherine D. Cummins

Since Specialization

Citations

This map shows the geographic impact of Katherine D. Cummins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine D. Cummins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine D. Cummins more than expected).

Fields of papers citing papers by Katherine D. Cummins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine D. Cummins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine D. Cummins. The network helps show where Katherine D. Cummins may publish in the future.

Co-authorship network of co-authors of Katherine D. Cummins

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine D. Cummins. A scholar is included among the top collaborators of Katherine D. Cummins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine D. Cummins. Katherine D. Cummins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models 2025 ·Science Translational Medicine ·Xin Du, Pei Kee Goh, Chenkai Ma, (unknown), (unknown), Laura H. Porter, Brendan E. Russ, Katherine D. Cummins, Kevin Sek, Clare Y. Slaney, Andrew M. Scott, Jane Oliaro, Paul J. Neeson, Gail P. Risbridger, Renea A. Taylor, Joseph A. Trapani, Stephen T. Turner, Phillip K. Darcy, Florian Wiede, Tony Tiganis	0
2	Increased STAT expression in Reed–Sternberg cells as a potential positive prognostication biomarker in Hodgkin lymphoma 2023 ·Pathology ·(unknown), Katherine D. Cummins, Patrick Hosking, Alan Pham, Eliza A. Hawkes, Stephen B. Ting	0
3	Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia 2023 ·Hematology/Oncology Clinics of North America ·Katherine D. Cummins, Saar Gill	5
4	Abstract 4074: Cellular immunotherapy targeting kappa myeloma antigen for the treatment of multiple myeloma 2023 ·Cancer Research ·Jessica Li, Nicole M. Haynes, Katherine D. Cummins, Kavitha Gowrishankar, (unknown), (unknown), (unknown), Jane Oliaro, Simon J. Harrison	1
5	Rapid manufacturing of non-activated potent CAR T cells breakdown → 2022 ·Nature Biomedical Engineering ·Saba Ghassemi, Joseph S. Durgin, Selene Nuñez-Cruz, Jai Patel, John Leferovich, Marilia Rita Pinzone, Feng Shen, Katherine D. Cummins, Gabriela Plesa, Adrian Cantu, Shantan Reddy, Frederic D. Bushman, Saar Gill, Una O’Doherty, Roddy S. O’Connor, Michael C. Milone	184
6	G-CSF Mobilized Apheresis As an Alternative Source of CAR T-Cells 2022 ·Blood ·Katherine D. Cummins, Arjun Gupta, Ofrat Beyar‐Katz, Ye Li, Paramita Chatterjee, (unknown), Olga Shestova, Monika A. Eiva, January Salas-McKee, (unknown), Krishnendu Roy, Saar Gill	1
7	Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL 2020 ·Journal of Clinical Investigation ·Christian Hurtz, Gerald Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne W. Lehman, Yong Li, Asen Bagashev, (unknown), Katherine D. Cummins, Janis K. Burkhardt, Alexander E. Perl, Martin Carroll, Sarah K. Tasian	32
8	Abstract B65: CT-0508, a novel CAR macrophage product directed against HER2, promotes a proinflammatory tumor microenvironment 2020 ·Cancer Immunology Research ·Konrad Gabrusiewicz, Nicholas R. Anderson, Xueqing Maggie Lu, Xinhe Shan, Olga Shestova, Nicholas Petty, Feng Shen, Maggie Schmierer, Andrew Best, Martha Zeeman, (unknown), Katherine D. Cummins, Saar Gill, Michael Klichinsky	4
9	Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? 2019 ·Haematologica ·Katherine D. Cummins, Saar Gill	52
10	Optimization of CRISPR-Cas9 knock-out of CD33 in human hematopoietic stem / progenitor cells for allogeneic transplantation in patients with acute myeloid leukemia 2019 ·Cytotherapy ·Katherine D. Cummins, January Salas-McKee, Irina Kulikovskaya, Mercy Gohil, Christopher L. Nobles, Frederic D. Bushman, Simon F. Lacey, Saar Gill	3
11	Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL 2019 ·Blood ·Christian Hurtz, Gerald Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne W. Lehman, Yong Li, (unknown), Katherine D. Cummins, Janis K. Burkhardt, Alexander E. Perl, Martin Carroll, Sarah K. Tasian	1
12	Will CAR T cell therapy have a role in AML? Promises and pitfalls 2018 ·Seminars in Hematology ·Katherine D. Cummins, Saar Gill	50
13	Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells 2017 ·Blood ·Katherine D. Cummins, Noelle V. Frey, Anne Marie Nelson, (unknown), Selina M. Luger, Randi Isaacs, Simon F. Lacey, Elizabeth O. Hexner, J. Joseph Melenhorst, Carl H. June, David L. Porter, Saar Gill	92
14	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1 2017 ·Leukemia ·(unknown), (unknown), Donia M. Moujalled, David Segal, Giovanna Pomilio, Sewa Rijal, Anissa M. Jabbour, Katherine D. Cummins, Kurt Lackovic, Piers Blombery, Ella R. Thompson, Paul G. Ekert, Guillaume Lessène, Stefan Glaser, David C.S. Huang, Andrew W. Roberts, Mark A. Guthridge, Andrew H. Wei	124
15	Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse 2017 ·Leukemia & lymphoma ·Katherine D. Cummins, Saar Gill	28
16	PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement 2015 ·BMJ Case Reports ·(unknown), Katherine D. Cummins, Alan Pham, George Grigoriadis	11
17	Numerous Howell‐Jolly bodies in a patient with idiopathic splenic calcification 2015 ·British Journal of Haematology ·Katherine D. Cummins, Glen Westall, George Grigoriadis	1
18	Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia 2014 ·Blood Cancer Journal ·Katherine D. Cummins, Stephen M. Jane, (unknown), (unknown), Robin Filshie, Gaurav Sutrave, Mark Hertzberg, (unknown), Steven Lane, Costas K. Yannakou, David Ritchie, James D’Rozario, J Black, (unknown), Andrew H. Wei	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact